SG Americas Securities LLC Acquires 5,197 Shares of Guardant Health, Inc. $GH

SG Americas Securities LLC lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 30.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,244 shares of the company’s stock after buying an additional 5,197 shares during the quarter. SG Americas Securities LLC’s holdings in Guardant Health were worth $2,055,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of GH. V Square Quantitative Management LLC bought a new position in Guardant Health during the fourth quarter worth $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health in the fourth quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $35,000. Finally, Parallel Advisors LLC boosted its position in shares of Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. BTIG Research raised their target price on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore upgraded Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target on the stock in a report on Tuesday, June 2nd. The Goldman Sachs Group initiated coverage on Guardant Health in a report on Friday, June 5th. They issued a “buy” rating and a $165.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Finally, Wolfe Research initiated coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $146.18.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $170.77 on Thursday. The stock has a market cap of $22.64 billion, a price-to-earnings ratio of -50.37 and a beta of 1.59. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $172.61. The firm’s 50-day simple moving average is $116.77 and its 200 day simple moving average is $105.20.

Insider Transactions at Guardant Health

In related news, CEO Amirali Talasaz sold 143,028 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the completion of the sale, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. This represents a 7.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. The trade was a 4.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 712,513 shares of company stock valued at $90,921,587. Corporate insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.